Takeda Completes Sale of Xiidra® to Novartis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.
“The completion of this transaction marks an important step in executing Takeda’s strategy, which is focused on optimizing our portfolio around the key business areas that are core to our long-term growth and creating the most value for our patients and shareholders,” said Christophe Weber, President and Chief Executive Officer of Takeda. “We are making solid progress on our commitment to simplify our portfolio and meet our deleveraging targets, while continuing to deliver highly-innovative medicines and transformative care to patients around the world and enhance long-term shareholder value. We are proud of the benefits Xiidra® has created for patients as part of Takeda, and confident that Novartis will be a strong steward of this innovative therapeutic.”
Takeda intends to use the proceeds from the sale to reduce its debt and accelerate deleveraging toward its target of 2x net debt/adjusted EBITDA in the medium term following closing of the Shire acquisition. As of March 31, 2019, Takeda has 5,048.9 billion yen in net debt outstanding and its net debt/adjusted EBITDA ratio is 4.7x. Takeda continues to target a net debt/adjusted EBITDA ratio of 2x within 3 to 5 years.
Xiidra® is the first and only prescription treatment approved by the U.S. Food and Drug Administration for both signs and symptoms of dry eye disease, with a mechanism of action that targets inflammation.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward looking statements often include the words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or words or terms of similar substance or the negative thereof. Any forward-looking statements in this document are based on the current assumptions and beliefs of Takeda in light of the information currently available to it. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s business, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding the safety or efficacy of marketed products or products candidates; and post-merger integration with acquired companies, any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Neither Takeda nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance or achievements could materially differ from expectations. Persons receiving this press release should not place undue reliance on forward looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.
Julia Ellwanger (Outside of Japan)
Kazumi Kobayashi (Japan)
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biolog-id Raises 30 Million Euros From Funds Managed by Xerys19.11.2019 13:30:00 CET | Press release
Biolog-id, a global leader in the traceability and management of sensitive health products (red blood cells, plasma, platelets and chemotherapy preparations), is announcing a campaign to raise 30 million euros from Xerys Funds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005064/en/ With this campaign, Biolog-id aims to exceed €200 M in turnover by 2023 and to join the clan of French unicorns — unlisted companies worth more than a billion dollars. “We are banking on a hyper-growth strategy, announced Biolog-id’s President and Founder, Jean-Claude Mongrenier. The funds gathered will enable us to accelerate the company’s international development through its main subsidiaries — North America, Middle East and Asia — and to extend the scope of action to other regions, in particular China. The market potential that Biolog-id hopes to exploit is currently valued by experts at nearly 4 billion dollars. It should increase co
FLIR Introduces StormCaster Payload Family for its SkyRaider and SkyRanger Unmanned Aerial Systems19.11.2019 13:00:00 CET | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) announced today the FLIR StormCaster™ family of Unmanned Aerial System (UAS) payloads for its SkyRanger® R70 and R80D SkyRaider® airframes. The new line launches with two multi-sensor products –StormCaster-T, which delivers continuous zoom and longwave infrared (LWIR) imaging; and StormCaster-L, which provides ultra-low-light imaging, tracking, and mapping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005274/en/ With two new products, FLIR Systems introduced its StormCaster family of next-generation drone payloads for its SkyRanger R70 and R80D SkyRaider airframes. The new StormCaster-T features a FLIR Boson thermal camera, which delivers sharp, clear images day or night at maximum range for object detection, recognition, and target acquisition. (Photo: Business Wire) StormCaster represents FLIR Systems’ next generation payload family for the company’s own UAS airframes gained throug
Moody’s Analytics Wins Model Validation Category in Chartis RiskTech100®19.11.2019 13:00:00 CET | Press release
Moody’s Analytics has won the Model Validation category in the Chartis RiskTech100® for the second straight year. It’s one of our seven category wins this year to go with a #4 overall ranking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005036/en/ In an increasingly challenging financial environment, there is an ever-greater need for validating and monitoring credit risk models. Our market-leading model validation solutions cover retail as well as commercial asset classes, for both internally developed and third-party models. Among our offerings is the cloud-based CAP™ solution. Powered by industry-leading Moody’s Analytics data and our wealth of risk modeling experience, the CAP solution lets firms tailor their models—both internal and third-party—to their own unique experience. Moody’s Analytics advisory services complement the CAP™ platform and all of our model validation offerings. Earlier this year, we earned t
Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies19.11.2019 13:00:00 CET | Press release
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies. Merck KGaA, Darmstadt, Germany, will utilize Personalis’ newest cancer immunogenomics platform, ImmunoID NeXT™, for clinical biomarker identification and development. ImmunoID NeXT, through innovative assays and analytics, provides a comprehensive view of each cancer’s genomics and immune microenvironment from a single, limited tumor sample. The platform is an end-to-end solution built for precision oncology biomarker discovery through to clinical applications, enabling simultaneous analysis of cancer mutations, the immune repertoire, neoantigens, tumor escape mechanisms, DNA repair pathways, human leukocyte antigens (including typing, loss of heterozygosity, and somatic mutation detection), tumor mutational bur
Social Football Summit 2019 to Take Place in Rome in Partnership With Lega Serie A19.11.2019 12:02:00 CET | Press release
Debates, meetings and networking dedicated to digital marketing and innovation in the world of football, are part of the programme of the second edition of the Social Football Summit scheduled for Wednesday 20 and Thursday 21/11/2019 at the Stadio Olympico in Rome (ITA). The event, organised by the start up "Social Media Soccer" and the digital company "Go Project", in partnership with the Lega Serie A, will feature 75 speakers during some thirty conferences, debates and other formats divided into two main themes: • The first is dedicated to the most significant and original initiatives in digital marketing and fan engagement. • The second is dedicated to digital transformation processes, sports technology, eSports, blockchain and other innovative projects. "The Lega Serie A is very aware of the need to exploit all the new digital marketing tools in order to be a leader in Italy and around the world. The market on which we want to focus strongly is the eSports market, which is now full
XPRIZE Announces New $10 Million Competition to Preserve Rainforests Across the Globe19.11.2019 12:00:00 CET | Press release
Today, XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially launched the $10M Rainforest XPRIZE. Registration is now open for teams interested in participating in the four-year global competition that calls on innovators to create technology capable of identifying and cataloging rainforest biodiversity and develop insights that may lead to a new bioeconomy through standing forests. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005397/en/ (Graphic: Business Wire) Rainforests remain undervalued, which has led to their rapid depletion over the past two decades. Having once covered 14% of the earth’s land surface, rainforests now cover a mere 6% of the planet, according to National Geographic. Specifically, the recent acceleration of the Amazon’s deforestation, due in part to illegal logging and mining as well as inefficient agricultural expansion, ha